Clinical trial

Phase I Study of Milatuzumab for Graft Versus Host Disease

NCT01663766

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2013-12-01

PhasePHASE1

Study timeline

Study start (actual)2013-12-01Date precision: month

Registry last updated2021-08-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

GVHD (Acute or Chronic)unresolved

Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)unresolved

Myelodysplastic Syndromeunresolved

Chronic Myelogenous Leukemia (CML)unresolved

Multiple Myeloma (MM)unresolved

Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)unresolved

Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)unresolved

Interventions

milatuzumabDRUG

Sponsors & collaborators

Gilead Scienceslead sponsor

Ohio State Universitycollaborator

Mapped research locations

ColumbusOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01663766 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.